World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
51998
World Ranking
8137
National Ranking
4216

Nancy L. Bartlett publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Nancy L. Bartlett sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 669 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Nancy L. Bartlett D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Nancy L. Bartlett sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 100 D-Index — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Nancy L. Bartlett is affiliated with Washington University in St. Louis in the United States. Their research primarily spans the field of Medicine, with a strong focus on oncology and related subfields including Pathology and Forensic Medicine, Genetics, Pulmonary and Respiratory Medicine, and Radiology, Nuclear Medicine and Imaging.

The main topics of their work revolve around various aspects of lymphoma and cancer treatment, with significant emphasis on Lymphoma Diagnosis and Treatment, CAR-T Cell Therapy Research, and Chronic Lymphocytic Leukemia Research. Additional areas covered include CNS Lymphoma Diagnosis and Treatment, Monoclonal and Polyclonal Antibodies Research, Lung Cancer Treatments and Mutations, and Viral-associated cancers and disorders.

Recent notable publications by Nancy L. Bartlett include:

  • Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study (2022, The Lancet Oncology)
  • Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma (2022, New England Journal of Medicine)
  • The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (2021, Annals of Oncology)
  • CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas (2020, Blood)
  • 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1) (2023, Blood)

Nancy L. Bartlett has collaborated frequently with several researchers, including:

  • Brad S. Kahl
  • John P. Leonard
  • Lihua E. Budde
  • Ranjana H. Advani
  • Marcus P. Watkins

The researcher's work is published extensively in journals such as Blood, Clinical Lymphoma Myeloma & Leukemia, Journal of Clinical Oncology, Blood Advances, and Hematological Oncology. This distribution reflects focused contributions to hematology and oncology fields.

Best Publications

  • Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Sattva S. Neelapu;Frederick L. Locke;Nancy L. Bartlett;Lazaros J. Lekakis

  • Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

    Frederick L Locke;Armin Ghobadi;Caron A Jacobson;David B Miklos

  • Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

    Roland Schmitz;George W. Wright;Da Wei Huang;Calvin A. Johnson

  • Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

    Jan A. Burger;Alessandra Tedeschi;Paul M. Barr;Tadeusz Robak

  • Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Anas Younes;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell

  • Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

    Thomas E. Witzig;Leo I. Gordon;Fernando Cabanillas;Myron S. Czuczman

  • Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

    Anas Younes;Nancy L Bartlett;John P Leonard;Dana A Kennedy

  • Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

    Barbara Pro;Ranjana Advani;Pauline Brice;Nancy L. Bartlett

  • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

    Jennifer A Woyach;Amy S Ruppert;Nyla A Heerema;Weiqiang Zhao

  • CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

    Ranjana Advani;Ian Flinn;Leslie Popplewell;Andres Forero

  • Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    Joseph M. Connors;Wojciech Jurczak;David J. Straus;Stephen M. Ansell

  • Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

    Owen A. O'Connor;Barbara Pro;Lauren Pinter-Brown;Nancy Bartlett

  • Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

    Frederick L. Locke;Sattva S. Neelapu;Nancy L. Bartlett;Tanya Siddiqi

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Barriers to Clinical Trial Participation by Older Women With Breast Cancer

    M. Margaret Kemeny;Bercedis L. Peterson;Alice B. Kornblith;Hyman B. Muss

  • Ibrutinib Combined With Bendamustine and Rituximab Compared With Placebo, Bendamustine, and Rituximab for Previously Treated Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma (HELIOS): A Randomised, Double-Blind, Phase 3 Study

    Asher Chanan-Khan;Paula Cramer;Fatih Demirkan;Graeme Fraser

  • Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin’s Disease: Mature Results of a Prospective Clinical Trial

    Sandra J. Horning;Richard T. Hoppe;Sheila Breslin;Nancy L. Bartlett

  • Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

    Gregory A. Wiseman;Leo I Gordon;Pratik S. Multani;Thomas E. Witzig

  • Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

    Steven M. Horwitz;Ranjana H. Advani;Nancy L. Bartlett;Eric D. Jacobsen

  • Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

    Leo I. Gordon;Fangxin Hong;Richard I. Fisher;Nancy L. Bartlett

Frequent Co-Authors

Ranjana H. Advani
Ranjana H. Advani Stanford University
John P. Leonard
John P. Leonard Cornell University
Bruce D. Cheson
Bruce D. Cheson Georgetown University
Jonathan W. Friedberg
Jonathan W. Friedberg University of Rochester
Leo I. Gordon
Leo I. Gordon Northwestern University
Eric D. Hsi
Eric D. Hsi Cleveland Clinic
Julie M. Vose
Julie M. Vose University of Nebraska Medical Center
Todd A. Fehniger
Todd A. Fehniger Washington University in St. Louis
Joseph M. Connors
Joseph M. Connors University of British Columbia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As you consider a career in medicine, it's important to explore various online degree options and pathways that can help you achieve your goals. Many students are now looking for flexible and affordable alternatives to traditional on-campus programs, especially in nursing and healthcare.

One of the most common questions is how much is online nursing school? Tuition can vary widely, but there are many reputable and affordable programs available. If you already have your RN, pursuing the cheapest rn to bsn program lets you advance your education quickly and cost-effectively.

For those interested in advanced research or academic roles, consider phd in nursing online programs, which offer flexibility and in-depth training. If you hold a non-nursing bachelor’s degree but want to switch careers, direct entry msn programs for non-nurses online provide a fast-track route into nursing practice.

Exploring these options can help you find the right career pathway in the healthcare field, tailored to your background, budget, and future ambitions.

Best Scientists Citing Nancy L. Bartlett

Trending Scientists